<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">CPR</journal-id>
<journal-id journal-id-type="hwp">spcpr</journal-id>
<journal-title>European Journal of Preventive Cardiology</journal-title>
<issn pub-type="ppub">2047-4873</issn>
<issn pub-type="epub">2047-4881</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1741826711414215</article-id>
<article-id pub-id-type="publisher-id">10.1177_1741826711414215</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Sports cardiology</subject>
<subj-group subj-group-type="heading">
<subject>Original scientific paper</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Impact of revised Task Force Criteria: distinguishing the athlete’s heart from ARVC/D using cardiac magnetic resonance imaging</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Luijkx</surname><given-names>Tim</given-names></name>
<xref ref-type="aff" rid="aff1-1741826711414215">1</xref>
<xref ref-type="corresp" rid="corresp1-1741826711414215"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Velthuis</surname><given-names>Birgitta K</given-names></name>
<xref ref-type="aff" rid="aff1-1741826711414215">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Prakken</surname><given-names>Niek HJ</given-names></name>
<xref ref-type="aff" rid="aff1-1741826711414215">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Cox</surname><given-names>Moniek GPJ</given-names></name>
<xref ref-type="aff" rid="aff2-1741826711414215">2</xref>
<xref ref-type="aff" rid="aff3-1741826711414215">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Bots</surname><given-names>Michiel L</given-names></name>
<xref ref-type="aff" rid="aff4-1741826711414215">4</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Mali</surname><given-names>Willem PThM</given-names></name>
<xref ref-type="aff" rid="aff1-1741826711414215">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Hauer</surname><given-names>Richard NW</given-names></name>
<xref ref-type="aff" rid="aff2-1741826711414215">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Cramer</surname><given-names>Maarten J</given-names></name>
<xref ref-type="aff" rid="aff2-1741826711414215">2</xref>
</contrib>
</contrib-group>
<aff id="aff1-1741826711414215"><label>1</label>Department of Radiology, University Medical Center Utrecht, Utrecht, The Netherlands.</aff>
<aff id="aff2-1741826711414215"><label>2</label>Department of Cardiology, University Medical Center Utrecht, Utrecht, The Netherlands.</aff>
<aff id="aff3-1741826711414215"><label>3</label>Interuniversity Cardiology Institute of the Netherlands, Utrecht, The Netherlands.</aff>
<aff id="aff4-1741826711414215"><label>4</label>Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands.</aff>
<author-notes>
<corresp id="corresp1-1741826711414215">T Luijkx, Department of Radiology, Room E01.132, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands Email: <email>tluijkx@gmail.com</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>8</month>
<year>2012</year>
</pub-date>
<volume>19</volume>
<issue>4</issue>
<fpage>885</fpage>
<lpage>891</lpage>
<history>
<date date-type="received"><day>9</day><month>9</month><year>2010</year></date>
<date date-type="accepted"><day>24</day><month>5</month><year>2011</year></date>
</history>
<permissions>
<copyright-statement>© The European Society of Cardiology 2011 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav</copyright-statement>
<copyright-year>2011</copyright-year>
<copyright-holder content-type="society">European Society of Cardiology</copyright-holder>
</permissions>
<abstract>
<p><bold>Background:</bold> Cardiac magnetic resonance (CMR) evaluation of athletes for arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D) is complicated by overlapping features such as right ventricular (RV) volume increase. The revised ARVC/D diagnostic Task Force Criteria (TFC) incorporate cut-off values for RV ejection fraction (EF) and RV end-diastolic volume (EDV) on CMR.</p>
<p><bold>Design:</bold> To distinguish ARVC/D patients from athletes we compared CMR ventricular volumes, function, TFC cut-off values, and LV/RV ratios since athletes show proportionate, and ARVC/D patients disproportionate, changes in LV and RV.</p>
<p><bold>Methods:</bold> Quantitative CMR parameters of 33 ARVC/D patients (64% male, mean age 45.4 years, diagnosed by revised TFC), 66 healthy athletes and 66 healthy non-athletes (sex and age matched) were compared using revised TFC and new cut-off values representing LV/RV balance.</p>
<p><bold>Results and conclusions:</bold> Absolute values for ARVC/D patients/athletes/non-athletes were: in males, RV EDV 149/133/106 ml/m<sup>2</sup>, ratio EDV LV/RV 0.70/0.91/0.93, RV EF 34/52/54%, LV EF 48/57/58%, ratio EF LV/RV 1.49/1.10/1.09; and in females, RV EDV 115/115/91 ml/m<sup>2</sup>, ratio EDV LV/RV 0.86/0.94/0.97, RV EF 43/54/58%, LV EF 52/57/61%, ratio EF LV/RV 1.23/1.08/1.04 (<italic>p</italic>-values &lt; 0.05). Areas under the ROC-curve are 0.68 (RV EDV index), 0.84 (LV/RV EDV ratio) and 0.93 (RV EF), demonstrating significantly (<italic>p</italic> &lt; 0.001) better performance of RV EF and LV/RV EDV ratio. If a wall motion abnormality is present (observed in 30 ARVC/D patients and not in healthy subjects), RV EF can help distinguish ARVC/D from physiological cardiac adaptation in athletes on CMR whereas RV EDV index cannot. A good alternative in athletes is the LV/RV EDV ratio, representing normal proportionate adaptation of both ventricles.</p>
</abstract>
<kwd-group>
<kwd>ARVC/D</kwd>
<kwd>athletes</kwd>
<kwd>cardiac MRI</kwd>
<kwd>CMR</kwd>
<kwd>Task Force Criteria</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-1741826711414215" sec-type="intro"><title>Introduction</title>
<p>Arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D) is a myocardial disease histologically characterized by replacement of myocardium with fibrous and fatty tissue, resulting in right ventricular (RV) dilatation and dysfunction, and ventricular arrhythmias. Although the estimated prevalence of ARVC/D is only 1:1000 to 1:5000,<sup><xref ref-type="bibr" rid="bibr1-1741826711414215">1</xref></sup> it is an important cause of sudden cardiac death (SCD) in young people and athletes.<sup><xref ref-type="bibr" rid="bibr2-1741826711414215">2</xref>,<xref ref-type="bibr" rid="bibr3-1741826711414215">3</xref></sup> Physical training has been reported to increase the risk of SCD.<sup><xref ref-type="bibr" rid="bibr4-1741826711414215">4</xref>,<xref ref-type="bibr" rid="bibr5-1741826711414215">5</xref></sup> Importantly, sudden cardiac death can be the first manifestation of ARVC/D, often occurring at an early age and often triggered by physical exertion. The increase in screening investigations has led to frequent requests for exclusion of ARVC/D on cardiac MRI (CMR). Overlapping features such as RV dilatation require careful assessment to distinguish ARVC/D from physiological cardiac adaptation (athlete’s heart).</p>
<p>For clinical diagnosis of ARVC/D, the Task Force Criteria (TFC), which combine family history, electrophysiological, morphological, functional, and histological criteria in six groups, are used.<sup><xref ref-type="bibr" rid="bibr6-1741826711414215">6</xref></sup> Although highly specific, these original TFC lack sensitivity for early disease.<sup><xref ref-type="bibr" rid="bibr7-1741826711414215">7</xref></sup> These criteria have been modified to improve sensitivity, while maintaining specificity, and to incorporate advances in genetic screening as well as quantitative imaging criteria.<sup><xref ref-type="bibr" rid="bibr8-1741826711414215">8</xref></sup> A definite ARVC/D diagnosis requires a minimum of four TFC points from different categories with major criteria yielding two points and minor criteria one point, fulfilled with either two major, one major and two minor, or four minor criteria. CMR can fulfil one major or one minor criterion in the imaging category ‘global or regional dysfunction and structural alterations’. The revised TFC for CMR require a combination of a wall motion abnormality (regional RV akinesia/dyskinesia or dyssynchronous RV contraction) and the fulfilment of one additional quantitative cardiac parameter: either an increased body surface area (BSA) corrected RV end-diastolic volume – (RV EDV) minor/major criteria: ≥100/≥110 ml/m<sup>2</sup> (male) or ≥90/≥100 ml/m<sup>2</sup> (female) – or a decreased RV ejection fraction – (RV EF) minor/major criteria: &gt;40% to ≤45%/≤40%.<sup><xref ref-type="bibr" rid="bibr8-1741826711414215">8</xref></sup></p>
<p>Physiological cardiac adaptation in athletes shows a proportionate (balanced) dilatation of both ventricles.<sup><xref ref-type="bibr" rid="bibr9-1741826711414215">9</xref></sup> LV/RV ratio measures could be useful differentiating parameters because a disproportionate ventricular dilatation is expected in ARVC/D patients, as histologically the RV is usually affected more extensively than the left ventricle (LV).<sup><xref ref-type="bibr" rid="bibr10-1741826711414215">10</xref>,<xref ref-type="bibr" rid="bibr11-1741826711414215">11</xref></sup> We compared cardiac ventricular dimensions, volumes and function of 33 ARVC/D patients with age- and sex-matched athletes and non-athletes and evaluated revised TFC and ratio measure cut-off values representing the balance of LV and RV changes.</p>
</sec>
<sec id="sec2-1741826711414215" sec-type="methods"><title>Methods</title>
<sec id="sec3-1741826711414215"><title>Study population</title>
<p>Thirty-three patients (64% male, average age males/females 49.6/38.1) diagnosed with ARVC/D according to the revised TFC (≥4 points)<sup><xref ref-type="bibr" rid="bibr8-1741826711414215">8</xref></sup> were included in this study. For comparison they were matched for sex and age to 66 healthy athletes (minimum of self-reported 9 hours/week sport) and 66 healthy non-athletes (maximum of 3 hours/week sport) from a large cohort.<sup><xref ref-type="bibr" rid="bibr12-1741826711414215">12</xref>,<xref ref-type="bibr" rid="bibr13-1741826711414215">13</xref></sup> All athletes performed high dynamic-high static sports according to the Mitchell classification,<sup><xref ref-type="bibr" rid="bibr14-1741826711414215">14</xref></sup> including 46 bi/triathletes, 12 rowers, and eight cyclists. Cardiac pathology was ruled out in the healthy study groups, using a cardiac MRI scan, an electrocardiogram, blood pressure measurement, family history, presence of disease and medication. The study was approved by the Institutional Ethics Committee and all subjects gave prior informed consent.</p>
</sec>
<sec id="sec4-1741826711414215"><title>Image acquisition</title>
<p>CMR imaging was performed on a 1.5 T MRI scanner (Achieva, Philips, Best, The Netherlands). ARVC/D patients underwent a standardized ARVC/D CMR imaging protocol including axial T1-weighted spin-echo imaging, multi-directional steady-state free precession (SSFP) cine imaging, and gadolinium late enhancement imaging. The scan protocol in athletes and non-athletes has been described in detail previously.<sup><xref ref-type="bibr" rid="bibr12-1741826711414215">12</xref></sup> All cines were viewed for wall motion abnormalities in all subjects.</p>
</sec>
<sec id="sec5-1741826711414215"><title>Image analysis</title>
<p>Analyses of the short axis cine images were performed on a workstation with semi-automated contour tracing software (View Forum cardiac package version R5.1V1L2.SP3, Philips, Best, The Netherlands). Blinded observers traced endocardial and epicardial contours of both ventricles, using an established reliable and reproducible contour tracing protocol.<sup><xref ref-type="bibr" rid="bibr15-1741826711414215">15</xref></sup></p>
<p>To conform with other CMR studies and the revised TFC (<sup><xref ref-type="bibr" rid="bibr16-1741826711414215">16</xref></sup>and personal communication with H. Tandri), RV and LV contours were traced including the RVOT and LVOT whereas papillary muscles and trabeculae were excluded from the endocardial border and included in the endocardial blood volume.<sup><xref ref-type="bibr" rid="bibr15-1741826711414215">15</xref></sup> End-diastolic ventricular diameters were also measured on the short axis images in a standardised way.<sup><xref ref-type="bibr" rid="bibr12-1741826711414215">12</xref></sup></p>
</sec>
<sec id="sec6-1741826711414215"><title>Statistics</title>
<p>Missing values ( &lt; 5% for all variables) were imputed with single regression techniques using all other available information about the patients.<sup><xref ref-type="bibr" rid="bibr17-1741826711414215">17</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr19-1741826711414215">19</xref></sup> BSA indexed CMR data using the Dubois &amp; Dubois formula<sup><xref ref-type="bibr" rid="bibr20-1741826711414215">20</xref></sup> are presented as mean ±1 SD.</p>
<p>Groups were compared using analysis of variance (ANOVA) with Bonferroni correction. Proportions of positive judgments per cut-off value (i.e. percentage meeting criterion at hand) of all groups were compared by Fisher’s exact test and the outcome was corrected for the number of tests.</p>
<p>Optimal cut-off values for ratio measures to assess their performance were derived from receiver-operator characteristic (ROC) curves coordinates by seeking the best trade-off between highest possible corresponding sensitivities and specificities. Areas under the ROC-curves were compared pairwise to identify a difference in identifying ARVC/D cases correctly. A two-sided <italic>p</italic>-value &lt; 0.05 was considered significant. All statistics were computed using SPSS version 15.0.</p>
</sec>
</sec>
<sec id="sec7-1741826711414215" sec-type="results"><title>Results</title>
<p>Baseline characteristics of all subjects are shown in <xref ref-type="table" rid="table1-1741826711414215">Table 1</xref>. The 33 ARVC/D patients met the revised TFC (mean 6.7 TFC points, median 7, range 4–10) in the following categories: dysfunction and structural alterations in 4/26 minor/major, repolarization abnormalities in 5/18, depolarization/conduction abnormalities in 7/13, arrhythmias in 16/13 and a positive family history in 1/24 patients (23 with a pathogenic gene mutation).
<table-wrap id="table1-1741826711414215" position="float"><label>Table 1.</label><caption><p>Baseline characteristics</p></caption>
<graphic alternate-form-of="table1-1741826711414215" xlink:href="10.1177_1741826711414215-table1.tif"/>
<table frame="hsides"><thead align="left">
<tr><th/>
<th colspan="2">Healthy non-athletes<hr/></th>
<th colspan="2">Healthy athletes<hr/></th>
<th colspan="2">ARVC/D patients<hr/></th></tr>
<tr>
<td>Sex (n)</td>
<td>M (42)</td>
<td>F (24)</td>
<td>M (42)</td>
<td>F (24)</td>
<td>M (21)</td>
<td>F (12)</td></tr></thead>
<tbody align="left">
<tr>
<td>Age (years)</td>
<td>44.3 ± 8.0</td>
<td>38.2 ± 13</td>
<td>48.6 ± 8.8</td>
<td>38.1 ± 14</td>
<td>49.6 ± 15</td>
<td>38.1 ± 17</td></tr>
<tr>
<td>Height (m)</td>
<td>185.0 ± 8.3</td>
<td>170.3 ± 6.1</td>
<td>180.9 ± 7.9</td>
<td>174.9 ± 6.2<sup><xref ref-type="table-fn" rid="table-fn1-1741826711414215">c</xref></sup></td>
<td>179.8 ± 7.3</td>
<td>173.0 ± 6.6</td></tr>
<tr>
<td>Weight (kg)</td>
<td>84.1 ± 12</td>
<td>64.8 ± 7.3</td>
<td>77.2 ± 8.6<sup><xref ref-type="table-fn" rid="table-fn1-1741826711414215">a</xref></sup></td>
<td>65.0 ± 6.8</td>
<td>78.1 ± 11</td>
<td>69.9 ± 17</td></tr>
<tr>
<td>BSA (m<sup>2</sup>)</td>
<td>2.08 ± 0.17</td>
<td>1.75 ± 0.11</td>
<td>1.97 ± 0.14<sup><xref ref-type="table-fn" rid="table-fn1-1741826711414215">a</xref></sup></td>
<td>1.79 ± 0.12</td>
<td>1.96 ± 0.15<sup><xref ref-type="table-fn" rid="table-fn1-1741826711414215">a</xref></sup></td>
<td>1.75 ± 0.18</td></tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1741826711414215"><p>BSA, body surface area. <sup>a</sup>Significantly different from non-athletes (<italic>P</italic> &lt; 0.05).</p></fn></table-wrap-foot>
</table-wrap></p>
<p>RV wall motion abnormalities on CMR were observed in 30 (91%) ARVC/D patients and in none of the healthy athletes and non-athletes. Only two healthy athletes had bulging of the apical RV free wall related to insertion of the moderator band, which was considered to be normal variation by an experienced radiologist and cardiologist. Both patients also met a major second imaging criterion (RV EDV index&gt;110 ml/m<sup>2</sup>) but no further TFC criteria for ARVC/D.</p>
<p>Ventricular volumes, wall mass and diameters indexed to BSA and ejection fractions are shown in <xref ref-type="table" rid="table2-1741826711414215">Table 2</xref>. ARVC/D patients’ RV EDV (mean male/female = 149/115 ml/m<sup>2</sup>) was similar to athletes (mean male/female = 133/115 ml/m<sup>2</sup>, <italic>p</italic> &lt; 0.05 for males) and both were significantly larger than healthy non-athletes (male/female non-athletes = 106/91 ml/m<sup>2</sup>, <italic>p</italic> &lt; 0.01). Conversely, in ARVC/D patients the LV EDV was similar to healthy non-athletes (mean 101 vs. 98 ml/m<sup>2</sup> in males and 97 vs. 88 ml/m<sup>2</sup> in females), whereas athletes had significantly larger LV EDV than both other groups (mean male/female = 120/108 ml/m<sup>2</sup>, <italic>p</italic> &lt; 0.01). In ARVC/D patients the reduced EF was more pronounced in the RV, and both LV and RV EF were lower (mean LV/RV EF 48/34% males; 52/43% females) than in healthy athletes (LV/RV EF 57/52% males and 57/54% females) and non-athletes (LV/RV EF 58/54% males; 61/58% females).
<table-wrap id="table2-1741826711414215" position="float"><label>Table 2.</label><caption><p>Quantitative ventricular parameters adjusted for body surface area</p></caption>
<graphic alternate-form-of="table2-1741826711414215" xlink:href="10.1177_1741826711414215-table2.tif"/>
<table frame="hsides"><thead align="left">
<tr><th/>
<th colspan="2">Healthy non-athletes<hr/></th>
<th colspan="2">Healthy athletes<sup><xref ref-type="table-fn" rid="table-fn2-1741826711414215">a</xref></sup><hr/></th>
<th colspan="2">ARVC/D patients<sup><xref ref-type="table-fn" rid="table-fn2-1741826711414215">e</xref></sup><hr/></th></tr>
<tr>
<td>Sex (n)</td>
<td>M (42)</td>
<td>F (24)</td>
<td>M (42)</td>
<td>F (24)</td>
<td>M (21)</td>
<td>F (12)</td></tr></thead>
<tbody align="left">
<tr>
<td colspan="7">RV</td></tr>
<tr>
<td> EF (%)<sup>l</sup></td>
<td>53.9 ± 5.8</td>
<td>58.3 ± 6.0</td>
<td>51.5 ± 4.6</td>
<td>53.5 ± 5.1<sup><xref ref-type="table-fn" rid="table-fn2-1741826711414215">b</xref></sup></td>
<td>34.4 ± 10<sup><xref ref-type="table-fn" rid="table-fn2-1741826711414215">h</xref>,<xref ref-type="table-fn" rid="table-fn2-1741826711414215">k</xref></sup></td>
<td>43.4 ± 8.8<sup><xref ref-type="table-fn" rid="table-fn2-1741826711414215">h</xref>,<xref ref-type="table-fn" rid="table-fn2-1741826711414215">k</xref></sup></td></tr>
<tr>
<td> EDV index (ml/m<sup>2</sup>)<sup>l</sup></td>
<td>106.1 ± 16</td>
<td>90.9 ± 12</td>
<td>132.9 ± 18<sup><xref ref-type="table-fn" rid="table-fn2-1741826711414215">d</xref></sup></td>
<td>115.3 ± 15<sup><xref ref-type="table-fn" rid="table-fn2-1741826711414215">d</xref></sup></td>
<td>149.0 ± 41<sup><xref ref-type="table-fn" rid="table-fn2-1741826711414215">h</xref>,<xref ref-type="table-fn" rid="table-fn2-1741826711414215">i</xref></sup></td>
<td>115.3 ± 33<sup><xref ref-type="table-fn" rid="table-fn2-1741826711414215">g</xref></sup></td></tr>
<tr>
<td> ESV index (ml/m<sup>2</sup>)</td>
<td>49.2 ± 11</td>
<td>37.9 ± 7.5</td>
<td>64.8 ± 13<sup><xref ref-type="table-fn" rid="table-fn2-1741826711414215">c</xref></sup></td>
<td>53.7 ± 9.6<sup><xref ref-type="table-fn" rid="table-fn2-1741826711414215">c</xref></sup></td>
<td>100.5 ± 41<sup><xref ref-type="table-fn" rid="table-fn2-1741826711414215">h</xref>,<xref ref-type="table-fn" rid="table-fn2-1741826711414215">k</xref></sup></td>
<td>67.5 ± 31<sup><xref ref-type="table-fn" rid="table-fn2-1741826711414215">h</xref>,<xref ref-type="table-fn" rid="table-fn2-1741826711414215">i</xref></sup></td></tr>
<tr>
<td> EDM index (ml/m<sup>2</sup>)</td>
<td>12.6 ± 2.9</td>
<td>10.7 ± 2.5</td>
<td>15.2 ± 2.9<sup><xref ref-type="table-fn" rid="table-fn2-1741826711414215">c</xref></sup></td>
<td>13.5 ± 3.0<sup><xref ref-type="table-fn" rid="table-fn2-1741826711414215">b</xref></sup></td>
<td>16.5 ± 5.6<sup><xref ref-type="table-fn" rid="table-fn2-1741826711414215">h</xref></sup></td>
<td>13.3 ± 4.8</td></tr>
<tr>
<td> EDD (mm)</td>
<td>44.8 ± 4.5</td>
<td>40.3 ± 6.3</td>
<td>52.5 ± 3.0<sup><xref ref-type="table-fn" rid="table-fn2-1741826711414215">b</xref></sup></td>
<td>45.8 ± 6.3</td>
<td>53.9 ± 2.9 <sup><xref ref-type="table-fn" rid="table-fn2-1741826711414215">g</xref></sup></td>
<td>44.2 ± 1.6</td></tr>
<tr>
<td colspan="7">LV</td></tr>
<tr>
<td> EF (%)</td>
<td>58.4 ± 6.2</td>
<td>60.8 ± 7.7</td>
<td>56.7 ± 5.4</td>
<td>57.4 ± 4.7</td>
<td>47.9 ± 8.8 <sup><xref ref-type="table-fn" rid="table-fn2-1741826711414215">h</xref>,<xref ref-type="table-fn" rid="table-fn2-1741826711414215">k</xref></sup></td>
<td>52.1 ± 8.7<sup><xref ref-type="table-fn" rid="table-fn2-1741826711414215">g</xref></sup></td></tr>
<tr>
<td> EDV index (ml/m<sup>2</sup>)</td>
<td>98.0 ± 12</td>
<td>87.8 ± 11</td>
<td>120.3 ± 15<sup><xref ref-type="table-fn" rid="table-fn2-1741826711414215">d</xref></sup></td>
<td>108.0 ± 15<sup><xref ref-type="table-fn" rid="table-fn2-1741826711414215">d</xref></sup></td>
<td>100.6 ± 17<sup>NS,</sup><sup><xref ref-type="table-fn" rid="table-fn2-1741826711414215">k</xref></sup></td>
<td>6.6 ± 20</td></tr>
<tr>
<td> ESV index (ml/m<sup>2</sup>)</td>
<td>40.8 ± 7.9</td>
<td>34.7 ± 9.1</td>
<td>52.3 ± 10<sup><xref ref-type="table-fn" rid="table-fn2-1741826711414215">d</xref></sup></td>
<td>45.9 ± 9.1 <sup><xref ref-type="table-fn" rid="table-fn2-1741826711414215">c</xref></sup></td>
<td>52.6 ± 13 <sup><xref ref-type="table-fn" rid="table-fn2-1741826711414215">h</xref></sup></td>
<td>47.0 ± 16 <sup><xref ref-type="table-fn" rid="table-fn2-1741826711414215">h</xref></sup></td></tr>
<tr>
<td> EDM index (ml/m<sup>2</sup>)</td>
<td>47.0 ± 8.2</td>
<td>33.8 ± 5.2</td>
<td>58.9 ± 12 <sup><xref ref-type="table-fn" rid="table-fn2-1741826711414215">d</xref></sup></td>
<td>46.5 ± 8.6 <sup><xref ref-type="table-fn" rid="table-fn2-1741826711414215">d</xref></sup></td>
<td>42.6 ± 6.9<sup>NS,</sup><sup><xref ref-type="table-fn" rid="table-fn2-1741826711414215">k</xref></sup></td>
<td>35.7 ± 6.6<sup>NS,</sup><sup><xref ref-type="table-fn" rid="table-fn2-1741826711414215">k</xref></sup></td></tr>
<tr>
<td> EDD (mm)</td>
<td>55.5 ± 3.3</td>
<td>51.9 ± 2.5</td>
<td>61.1 ± 2.9</td>
<td>55.6 ± 4.2 <sup><xref ref-type="table-fn" rid="table-fn2-1741826711414215">b</xref></sup></td>
<td>55.2 ± 7.1</td>
<td>55.9 ± 5.1</td></tr>
<tr>
<td colspan="7">Ratio measures</td></tr>
<tr>
<td> LV/RV EF</td>
<td>1.09 ± 0.09</td>
<td>1.04 ± 0.09</td>
<td>1.10 ± 0.08</td>
<td>1.08 ± 0.06</td>
<td>1.49 ± 0.43 <sup><xref ref-type="table-fn" rid="table-fn2-1741826711414215">h</xref>,<xref ref-type="table-fn" rid="table-fn2-1741826711414215">k</xref></sup></td>
<td>1.23 ± 0.22 <sup><xref ref-type="table-fn" rid="table-fn2-1741826711414215">h</xref>,<xref ref-type="table-fn" rid="table-fn2-1741826711414215">j</xref></sup></td></tr>
<tr>
<td> LV/RV EDV</td>
<td>0.93 ± 0.08</td>
<td>0.97 ± 0.10</td>
<td>0.91 ± 0.07</td>
<td>0.94 ± 0.05</td>
<td>0.70 ± 0.15 <sup><xref ref-type="table-fn" rid="table-fn2-1741826711414215">h</xref>,<xref ref-type="table-fn" rid="table-fn2-1741826711414215">k</xref></sup></td>
<td>0.86 ± 0.14 <sup><xref ref-type="table-fn" rid="table-fn2-1741826711414215">g</xref></sup></td></tr>
<tr>
<td> LV/RV ESV</td>
<td>0.85 ± 0.16</td>
<td>0.92 ± 0.21</td>
<td>0.82 ± 0.13</td>
<td>0.86 ± 0.10</td>
<td>0.57 ± 0.18 <sup><xref ref-type="table-fn" rid="table-fn2-1741826711414215">h</xref>,<xref ref-type="table-fn" rid="table-fn2-1741826711414215">k</xref></sup></td>
<td>0.74 ± 0.21<sup><xref ref-type="table-fn" rid="table-fn2-1741826711414215">f</xref></sup></td></tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-1741826711414215"><p>EF, ejection fraction; EDV, end-diastolic volume; ESV, end-systolic volume; EDM, end-diastolic mass; EDD, end-diastolic diameter. <sup>a</sup><italic>P</italic> values for significant differences between non-athletes and athletes are; <sup>b</sup><italic>P</italic> &lt; 0.05, <sup>c</sup><italic>P</italic> &lt; 0.005, <sup>d</sup><italic>P</italic> &lt; 0.005, <sup>e</sup><italic>P</italic> values for significant differences between non-athletes and ARVC/D patients are: <sup>f</sup><italic>P</italic> &lt; 0.05, <sup>g</sup><italic>P</italic> &lt; 0.005, <sup>h</sup><italic>P</italic> &lt; 0.0005; <italic>P</italic> values for significant differences between athletes and ARVC/D patients are; <sup>i</sup><italic>P</italic> &lt; 0.05, <sup>j</sup><italic>P</italic> &lt; 0.005, <sup>k</sup><italic>P</italic> &lt; 0.0005; <sup>l</sup>Parameters used in revised Task Force Criteria.</p></fn></table-wrap-foot>
</table-wrap></p>
<p><xref ref-type="table" rid="table3-1741826711414215">Table 3</xref> shows the percentage of subjects per group meeting a cut-off value. Only 8/2% of healthy male/female subjects met the minor criterion for RV EF and none met the major criterion, whereas 86/67% of male and 58/33% of female ARVC/D patients met the minor or major criterion respectively (<italic>p</italic> &lt; 0.01), illustrating that RV EF is a useful criterion. However, the minor/major RV EDV index criterion was met in 93/86% of male and 100/88% of female healthy athletes, and even 62/50% of male and 54/13% of female healthy non-athletes, compared to 90/90% of male and 82/55% of female ARVC/D patients. In search of a measure that may possibly better distinguish ARVC/D patients from athletes we computed LV/RV ratios derived from EF, EDV and ESV (<xref ref-type="table" rid="table2-1741826711414215">Table 2</xref>). Corresponding results of two cut-off values derived from the ROC-curves for each ratio measure are presented in <xref ref-type="table" rid="table3-1741826711414215">Table 3</xref>. Additionally, 2-way tables show the performance of the most relevant variables (<xref ref-type="table" rid="table4-1741826711414215">Table 4</xref>).
<table-wrap id="table3-1741826711414215" position="float"><label>Table 3.</label><caption><p>Percentages meeting cut-off values of revised TFC variables and ratio measures</p></caption>
<graphic alternate-form-of="table3-1741826711414215" xlink:href="10.1177_1741826711414215-table3.tif"/>
<table frame="hsides"><thead align="left">
<tr><th/>
<th colspan="2">Healthy non-athletes<hr/></th>
<th colspan="2">Healthy athletes<hr/></th>
<th colspan="2">ARVC/D patients<hr/></th></tr>
<tr>
<td>Sex (n)</td>
<td>M (42)</td>
<td>F (24)</td>
<td>M (42)</td>
<td>F (24)</td>
<td>M (21)</td>
<td>F (12)</td></tr></thead>
<tbody align="left">
<tr>
<td colspan="7">Revised TFC</td></tr>
<tr>
<td> RV EF &lt; 45% (%)</td>
<td>10</td>
<td>0</td>
<td>7</td>
<td>4</td>
<td>86<sup><xref ref-type="table-fn" rid="table-fn3-1741826711414215">a</xref></sup></td>
<td>58<sup><xref ref-type="table-fn" rid="table-fn3-1741826711414215">a</xref></sup></td></tr>
<tr>
<td> RV EF &lt; 40% (%)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>67<sup><xref ref-type="table-fn" rid="table-fn3-1741826711414215">a</xref></sup></td>
<td>33<sup><xref ref-type="table-fn" rid="table-fn3-1741826711414215">a</xref></sup></td></tr>
<tr>
<td> RV EDV index &gt; 90 ml/m<sup>2</sup> (%)</td>
<td/>
<td>54</td>
<td/>
<td>100</td>
<td/>
<td>82</td></tr>
<tr>
<td> RV EDV index &gt; 100 ml/m<sup>2</sup> (%)</td>
<td>62<sup><xref ref-type="table-fn" rid="table-fn3-1741826711414215">a</xref></sup></td>
<td>13<sup><xref ref-type="table-fn" rid="table-fn3-1741826711414215">a</xref></sup></td>
<td>93</td>
<td>88</td>
<td>90</td>
<td>55</td></tr>
<tr>
<td> RV EDV index &gt; 110 ml/m<sup>2</sup> (%)</td>
<td>50<sup><xref ref-type="table-fn" rid="table-fn3-1741826711414215">a</xref></sup></td>
<td/>
<td>86</td>
<td/>
<td>90</td>
<td/></tr>
<tr>
<td> Meeting minor criterion TFC (%)</td>
<td>62<sup><xref ref-type="table-fn" rid="table-fn3-1741826711414215">a</xref></sup></td>
<td>54</td>
<td>93</td>
<td>100</td>
<td>90</td>
<td>82</td></tr>
<tr>
<td> Meeting major criterion TFC (%)</td>
<td>50<sup><xref ref-type="table-fn" rid="table-fn3-1741826711414215">a</xref></sup></td>
<td>13</td>
<td>86</td>
<td>88</td>
<td>90</td>
<td>55</td></tr>
<tr>
<td colspan="7">Ratio measures</td></tr>
<tr>
<td> Ratio EF LV/RV &gt; 1.20 (%)</td>
<td>12</td>
<td>8</td>
<td>12</td>
<td>4</td>
<td>81<sup><xref ref-type="table-fn" rid="table-fn3-1741826711414215">a</xref></sup></td>
<td>50<sup><xref ref-type="table-fn" rid="table-fn3-1741826711414215">a</xref></sup></td></tr>
<tr>
<td> Ratio EF LV/RV &gt; 1.25 (%)</td>
<td>7</td>
<td>0</td>
<td>2</td>
<td>4</td>
<td>67<sup><xref ref-type="table-fn" rid="table-fn3-1741826711414215">a</xref></sup></td>
<td>41<sup><xref ref-type="table-fn" rid="table-fn3-1741826711414215">a</xref></sup></td></tr>
<tr>
<td> Ratio EDV LV/RV&lt; 0.85 (%)</td>
<td>14</td>
<td>13</td>
<td>12</td>
<td>4</td>
<td>86<sup><xref ref-type="table-fn" rid="table-fn3-1741826711414215">a</xref></sup></td>
<td>42</td></tr>
<tr>
<td> Ratio EDV LV/RV&lt; 0.80 (%)</td>
<td>5</td>
<td>0</td>
<td>5</td>
<td>0</td>
<td>71<sup><xref ref-type="table-fn" rid="table-fn3-1741826711414215">a</xref></sup></td>
<td>33<sup><xref ref-type="table-fn" rid="table-fn3-1741826711414215">a</xref></sup></td></tr>
<tr>
<td> Ratio ESV LV/RV&lt; 0.70 (%)</td>
<td>17</td>
<td>13</td>
<td>17</td>
<td>4</td>
<td>76<sup><xref ref-type="table-fn" rid="table-fn3-1741826711414215">a</xref></sup></td>
<td>42</td></tr>
<tr>
<td> Ratio ESV LV/RV&lt; 0.65 (%)</td>
<td>12</td>
<td>8</td>
<td>7</td>
<td>0</td>
<td>57<sup><xref ref-type="table-fn" rid="table-fn3-1741826711414215">a</xref></sup></td>
<td>25</td></tr>
<tr>
<td> Meeting altered minor criterion (%)<sup><xref ref-type="table-fn" rid="table-fn3-1741826711414215">b</xref></sup></td>
<td>12</td>
<td>8</td>
<td>12</td>
<td>4</td>
<td>86<sup><xref ref-type="table-fn" rid="table-fn3-1741826711414215">a</xref></sup></td>
<td>58<sup><xref ref-type="table-fn" rid="table-fn3-1741826711414215">a</xref></sup></td></tr>
<tr>
<td> Meeting altered major criterion (%)<sup><xref ref-type="table-fn" rid="table-fn3-1741826711414215">b</xref></sup></td>
<td>7</td>
<td>0</td>
<td>2</td>
<td>4</td>
<td>67<sup><xref ref-type="table-fn" rid="table-fn3-1741826711414215">a</xref></sup></td>
<td>41<sup><xref ref-type="table-fn" rid="table-fn3-1741826711414215">a</xref></sup></td></tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-1741826711414215"><p>Percentages indicate proportion of group meeting the specified criterion in the first column. <sup>a</sup>Significantly different (<italic>p</italic> &lt; 0.05) from all other groups. <sup>b</sup>Altered minor/major criterion represents a combination of RV EF and Ratio LV/RV EDV, which is overall the best performing combination of variables.</p></fn></table-wrap-foot>
</table-wrap>
<table-wrap id="table4-1741826711414215" position="float"><label>Table 4.</label><caption><p>Performance comparison of revised TFC cut-off values and new variable cut-off values</p></caption>
<graphic alternate-form-of="table4-1741826711414215" xlink:href="10.1177_1741826711414215-table4.tif"/>
<table frame="hsides">
<tbody align="left">
<tr>
<td colspan="8">Revised TFC cut-off values</td></tr>
<tr>
<td> RV EDV major TFC</td>
<td>ARVC/D+</td>
<td>ARVC/D-</td>
<td/>
<td>RV EDV minor TFC</td>
<td>ARVC/D+</td>
<td>ARVC/D-</td>
<td/></tr>
<tr>
<td> Test positive</td>
<td>25</td>
<td>81</td>
<td>PPV 24%</td>
<td>Test positive</td>
<td>28</td>
<td>102</td>
<td>PPV 22%</td></tr>
<tr>
<td> Test negative</td>
<td>5</td>
<td>51</td>
<td>NPV 91%</td>
<td>Test negative</td>
<td>5</td>
<td>30</td>
<td>NPV 86%</td></tr>
<tr>
<td> Aens/spec</td>
<td>83%</td>
<td>39%</td>
<td/>
<td>Sens/spec</td>
<td>85%</td>
<td>23%</td>
<td/></tr>
<tr>
<td colspan="8">New variable cut-off values</td></tr>
<tr>
<td> EDV ratio &lt;0.80</td>
<td>ARVC/D+</td>
<td>ARVC/D-</td>
<td/>
<td>EDV ratio &lt;0.85</td>
<td>ARVC/D+</td>
<td>ARVC/D-</td>
<td/></tr>
<tr>
<td> Test positive</td>
<td>19</td>
<td>4</td>
<td>PPV 83%</td>
<td>Test positive</td>
<td>23</td>
<td>15</td>
<td>PPV 61%</td></tr>
<tr>
<td> Test negative</td>
<td>14</td>
<td>128</td>
<td>NPV 90%</td>
<td>Test negative</td>
<td>10</td>
<td>117</td>
<td>NPV 92%</td></tr>
<tr>
<td> Sens/spec</td>
<td>58%</td>
<td>97%</td>
<td/>
<td>Sens/spec</td>
<td>70%</td>
<td>87%</td>
<td/></tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn4-1741826711414215"><p>Sens, sensitivity; spec, specificity; PPV, positive predictive value; NPV, negative predictive value.</p></fn>
</table-wrap-foot>
</table-wrap></p>
<p>The LV/RV EF ratio does not perform better than the absolute RV EF (area under the ROC-curve (AUC) RV EF 0.93, EF ratio 0.84, <italic>p</italic> = 0.06). Conversely, the LV/RV EDV ratio performed significantly better than the BSA indexed RV EDV values (AUC EDV ratio 0.84, RV EDV 0.68, <italic>p</italic> &lt; 0.01), resulting in high numbers of ARVC/D patients and low numbers of athletes and non-athletes exceeding the cut-off value (ARVC/D/athletes/non-athletes = minor: males 86/12/14%, females 42/4/13%; major: males 71/5/5%, females 33/0/0%). While the EDV ratio gave much better results than the RV EDV index, there was no difference between ESV ratio and RV ESV index (<italic>p</italic> = 0.89). Both ESV measures performed similar to EDV ratio (AUC ESV ratio 0.81/RV ESV index 0.82, <italic>p</italic> = 0.06/0.66 compared to EDV ratio 0.84).</p>
<p><xref ref-type="table" rid="table4-1741826711414215">Table 4</xref> shows that positive and negative predictive value (PPV/NPV) are both very high for EDV ratio, whereas RV EDV index shows a much lower PPV. <xref ref-type="fig" rid="fig1-1741826711414215">Figure 1</xref> shows ROC-curves of combinations of ratio measures and BSA corrected absolute measures. These curves show a significant improvement for EDV ratio, ESV ratio and RV ESV index compared to RV EDV index, whereas EF ratio is similar, but not better than absolute RV EF. The best combination of measures is RV EF and EDV ratio (AUC 0.93;0.84).
<fig id="fig1-1741826711414215" position="float"><label>Figure 1.</label><caption><p>Receiver operating characteristic (ROC) curves visualising correct identification of ARVC/D. *Area under the ROC-curve significantly different from all other curves.</p></caption><graphic xlink:href="10.1177_1741826711414215-fig1.tif"/></fig></p>
</sec>
<sec id="sec8-1741826711414215" sec-type="discussion"><title>Discussion</title>
<p>Our data show that the revised TFC work well in distinguishing ARVC/D from physiological cardiac adaptation in athletes since no true wall motion abnormalities were observed. For the additional quantitative imaging criterion RV EF is suitable, whereas RV EDV index is not. More athletes fulfil the RV EDV index criterion than ARVC/D patients. As an alternative volume criterion, LV/RV EDV ratio measures discriminate better between the balanced ventricular adaptation in healthy athletes and disbalanced dilatation in ARVC/D patients.</p>
<p>Although ARVC/D is rare, CMR is frequently requested to help rule out possible ARVC/D. However, CMR is also an important source of misdiagnosis.<sup><xref ref-type="bibr" rid="bibr21-1741826711414215">21</xref>,<xref ref-type="bibr" rid="bibr22-1741826711414215">22</xref></sup> Finding an RV wall motion abnormality is a prerequisite for fulfilling the revised Task Force Criteria for ARVC/D, but this assessment is not always unequivocal.<sup><xref ref-type="bibr" rid="bibr21-1741826711414215">21</xref>,<xref ref-type="bibr" rid="bibr23-1741826711414215">23</xref></sup> Bulging related to the insertion site of the moderator band is also found in healthy people,<sup><xref ref-type="bibr" rid="bibr22-1741826711414215">22</xref></sup> as seen in two of the healthy athletes in this study. While true wall motion abnormalities were absent in all our healthy subjects, incorrect interpretation of possible wall motion abnormalities would nearly always lead to incorrect fulfilment of the CMR criteria of the revised TFC. Although imaging alone is never conclusive for ARVC/D diagnosis, it is an important step towards a possible false-positive diagnosis leading to negative sports advice in healthy athletes.</p>
<p>Important LV involvement is not uncommon in progressive ARVC/D disease, but the RV dilatation of ARVC/D patients is usually disproportionate compared to the LV.<sup><xref ref-type="bibr" rid="bibr16-1741826711414215">16</xref>,<xref ref-type="bibr" rid="bibr24-1741826711414215">24</xref></sup> Our study confirms this ventricular disbalance with lower LV/RV EDV ratios in ARVC/D patients as compared to healthy athletes and non-athletes. Smaller LV/RV EDV ratios in ARVC/D patients in comparison to athletes and healthy controls have also been found in an echocardiographic study by Bauce et al.<sup><xref ref-type="bibr" rid="bibr24-1741826711414215">24</xref></sup> Moreover, ratio measures can be calculated without knowing length and weight, which are required for BSA indexation of RV EDV.</p>
<p>The North American arrhythmogenic right ventricular dysplasia study group concludes that quantitative CMR evaluation of the RV using cut-off values for several variables mostly results in a high specificity (83–95%) – but not always in an equally high sensitivity – for ARVC/D diagnosis. Only RV EF resulted in a high sensitivity (85%), whereas other variables, such as RV EDV, had a sensitivity around 50%.<sup><xref ref-type="bibr" rid="bibr16-1741826711414215">16</xref></sup> In a large study by Marcus et al.<sup><xref ref-type="bibr" rid="bibr25-1741826711414215">25</xref></sup> on the diagnostic performance of various testing modalities for diagnosing ARVC/D, the added benefit of CMR was very small (reduction of chi-square score from 61.44 to 61.24 after removal of CMR from a predictive model including seven variables) and most often led to disparities between referring centres and core laboratory. They did not evaluate the usefulness of CMR in diagnosing ARVC/D in athletes.</p>
<p>Myocardial fatty infiltration, end-diastolic RV diameters, RV free wall thinning and late gadolinium enhancement (LGE) of myocardial fibrosis of the RV wall are not considered in this study because, although often seen in ARVC/D patients, they are not part of both the original and the revised TFC and can lead to misdiagnosis.<sup><xref ref-type="bibr" rid="bibr26-1741826711414215">26</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr28-1741826711414215">28</xref></sup> Fatty infiltration is also seen in healthy individuals and increases with age and body weight.<sup><xref ref-type="bibr" rid="bibr8-1741826711414215">8</xref></sup> End-diastolic RV diameter performs worse than quantitative EF and end-diastolic volumes to identify ARVC/D and shows a large overlap with athletes.<sup><xref ref-type="bibr" rid="bibr13-1741826711414215">13</xref>,<xref ref-type="bibr" rid="bibr16-1741826711414215">16</xref></sup> Although LGE correlates well with the presence of ARVC/D<sup><xref ref-type="bibr" rid="bibr27-1741826711414215">27</xref>,<xref ref-type="bibr" rid="bibr29-1741826711414215">29</xref></sup> and is performed in all patients suspected of ARVC/D, it was considered unethical to administer a gadolinium contrast agent to healthy volunteers. LGE imaging not only facilitates ARVC/D diagnosis but it also helps to provide information for a differential diagnosis (e.g. sarcoidosis, myocarditis).</p>
<p>Several CMR studies have reported on physiological cardiac adaptation, including recent work from our own study group.<sup><xref ref-type="bibr" rid="bibr12-1741826711414215">12</xref>,<xref ref-type="bibr" rid="bibr13-1741826711414215">13</xref></sup> However, few studies have focused on the diagnostic imaging difficulties of ruling out ARVC/D in athletes. Bauce et al.<sup><xref ref-type="bibr" rid="bibr24-1741826711414215">24</xref></sup> only present echocardiographic data on differentiating physiological cardiac adaptation from ARVC/D. The difficulties of differentiating ARVC/D and RVOT ventricular tachycardia (RVOT-VT) in elite athletes are discussed by Whyte et al.,<sup><xref ref-type="bibr" rid="bibr23-1741826711414215">23</xref></sup> illustrated by a case report of an elite athlete with idiopathic RVOT-VT. La Gerche et al.<sup><xref ref-type="bibr" rid="bibr30-1741826711414215">30</xref></sup> investigated 47 athletes with complex ventricular arrhythmias of RV morphology, excluding idiopathic RVOT-VT. Although 51% fulfilled definite ARVC/D criteria, the prevalence of pathological gene mutations was lower (12%) than in familial ARVC/D (27–52%). This supports the existence of an (intense endurance) exercise-induced ARVC-like syndrome, which is also associated with fatal arrhythmias.</p>
<sec id="sec9-1741826711414215"><title>Study limitations</title>
<p>No athletes with ARVC/D or ventricular arrhythmias were included in this study, complicating assessment of specificity, NPV and PPV for athletes specifically. As a substitute, we plotted ROC-curves using all subjects in this study. Because ARVC/D is an infrequent disease and competitive sport is discouraged in ARVC/D patients, it is virtually impossible to include highly trained ARVC/D patients and therefore these are the best obtainable estimates to assess the usefulness of the proposed measurements in athletes. A higher number of women might have reinforced the significant findings in men, although the same trends are observed in women. We did not investigate criteria from other TFC categories, which may also play a role in the misdiagnosis of athletes with ARVC/D.</p>
</sec>
</sec>
<sec id="sec10-1741826711414215" sec-type="conclusions"><title>Conclusions</title>
<p>Our study shows that the revised TFC quantitative CMR cut-off values work well in healthy athletes as the required wall motion abnormality is not observed. If a RV wall motion abnormality is present, RV EF is a suitable parameter to distinguish ARVC/D patients from athletes whereas RV EDV index is not. Using RV EDV index could result in false ARVC/D diagnoses in athletes. As an alternative we suggest using the ratio of LV/RV EDV in athletes, which best represents the balance of physiological ventricular changes.</p>
</sec>
</body>
<back>
<sec id="sec11-1741826711414215"><title>Funding</title>
<p>MGPJ Cox received funding from the Interuniversity Cardiology Institute of the Netherlands Project 06901 and the Netherlands Heart Foundation Grant 2007B139.</p>
</sec>
<sec id="sec12-1741826711414215"><title>Conflict of interest</title>
<p>The authors declare no conflict of interest.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="bibr1-1741826711414215"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Basso</surname><given-names>C</given-names></name><name><surname>Corrado</surname><given-names>D</given-names></name><name><surname>Marcus</surname><given-names>FI</given-names></name><name><surname>Nava</surname><given-names>A</given-names></name><name><surname>Thiene</surname><given-names>G</given-names></name></person-group>. <article-title>Arrhythmogenic right ventricular cardiomyopathy</article-title>. <source>Lancet</source> <year>2009</year>; <volume>373</volume>: <fpage>1289</fpage>–<lpage>1300</lpage>.</citation></ref>
<ref id="bibr2-1741826711414215"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Corrado</surname><given-names>D</given-names></name><name><surname>Thiene</surname><given-names>G</given-names></name><name><surname>Nava</surname><given-names>A</given-names></name><name><surname>Rossi</surname><given-names>L</given-names></name><name><surname>Pennelli</surname><given-names>N</given-names></name></person-group>. <article-title>Sudden death in young competitive athletes: clinicopathologic correlations in 22 cases</article-title>. <source>Am J Med</source> <year>1990</year>; <volume>89</volume>: <fpage>588</fpage>–<lpage>596</lpage>.</citation></ref>
<ref id="bibr3-1741826711414215"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thiene</surname><given-names>G</given-names></name><name><surname>Nava</surname><given-names>A</given-names></name><name><surname>Corrado</surname><given-names>D</given-names></name><name><surname>Rossi</surname><given-names>L</given-names></name><name><surname>Pennelli</surname><given-names>N</given-names></name></person-group>. <article-title>Right ventricular cardiomyopathy and sudden death in young people</article-title>. <source>N Engl J Med</source> <year>1988</year>; <volume>318</volume>: <fpage>129</fpage>–<lpage>133</lpage>.</citation></ref>
<ref id="bibr4-1741826711414215"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Corrado</surname><given-names>D</given-names></name><name><surname>Basso</surname><given-names>C</given-names></name><name><surname>Schiavon</surname><given-names>M</given-names></name><name><surname>Pelliccia</surname><given-names>A</given-names></name><name><surname>Thiene</surname><given-names>G</given-names></name></person-group>. <article-title>Pre-participation screening of young competitive athletes for prevention of sudden cardiac death</article-title>. <source>J Am Coll Cardiol</source> <year>2008</year>; <volume>52</volume>: <fpage>1981</fpage>–<lpage>1989</lpage>.</citation></ref>
<ref id="bibr5-1741826711414215"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pelliccia</surname><given-names>A</given-names></name><name><surname>Corrado</surname><given-names>D</given-names></name><name><surname>Bjørnstad</surname><given-names>HH</given-names></name><name><surname>Panhuyzen-Goedkoop</surname><given-names>N</given-names></name><name><surname>Urhausen</surname><given-names>A</given-names></name><name><surname>Carre</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Recommendations for participation in competitive sport and leisure-time physical activity in individuals with cardiomyopathies, myocarditis and pericarditis</article-title>. <source>Eur J Cardiovasc Prev Rehabil</source> <year>2006</year>; <volume>13</volume>: <fpage>876</fpage>–<lpage>885</lpage>.</citation></ref>
<ref id="bibr6-1741826711414215"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McKenna</surname><given-names>WJ</given-names></name><name><surname>Thiene</surname><given-names>G</given-names></name><name><surname>Nava</surname><given-names>A</given-names></name><name><surname>Fontaliran</surname><given-names>F</given-names></name><name><surname>Blomstrom-Lundqvist</surname><given-names>C</given-names></name><name><surname>Fontaine</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Diagnosis of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Task Force of the Working Group Myocardial and Pericardial Disease of the European Society of Cardiology and of the Scientific Council on Cardiomyopathies of the International Society and Federation of Cardiology</article-title>. <source>Br Heart J</source> <year>1994</year>; <volume>71</volume>: <fpage>215</fpage>–<lpage>218</lpage>.</citation></ref>
<ref id="bibr7-1741826711414215"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sen-Chowdhry</surname><given-names>S</given-names></name><name><surname>Lowe</surname><given-names>MD</given-names></name><name><surname>Sporton</surname><given-names>SC</given-names></name><name><surname>McKenna</surname><given-names>WJ</given-names></name></person-group>. <article-title>Arrhythmogenic right ventricular cardiomyopathy: clinical presentation, diagnosis, and management</article-title>. <source>Am J Med</source> <year>2004</year>; <volume>117</volume>: <fpage>685</fpage>–<lpage>695</lpage>.</citation></ref>
<ref id="bibr8-1741826711414215"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Marcus</surname><given-names>FI</given-names></name><name><surname>McKenna</surname><given-names>WJ</given-names></name><name><surname>Sherrill</surname><given-names>D</given-names></name><name><surname>Basso</surname><given-names>C</given-names></name><name><surname>Bauce</surname><given-names>B</given-names></name><name><surname>Bluemke</surname><given-names>DA</given-names></name><etal/></person-group>. <article-title>Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the Task Force Criteria</article-title>. <source>Eur Heart J</source> <year>2010</year>; <volume>31</volume>: <fpage>806</fpage>–<lpage>814</lpage>.</citation></ref>
<ref id="bibr9-1741826711414215"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Prakken</surname><given-names>NH</given-names></name><name><surname>Velthuis</surname><given-names>BK</given-names></name><name><surname>Bosker</surname><given-names>AC</given-names></name><name><surname>Mosterd</surname><given-names>A</given-names></name><name><surname>Teske</surname><given-names>AJ</given-names></name><name><surname>Mali</surname><given-names>WP</given-names></name><etal/></person-group>. <article-title>Relationship of ventricular and atrial dilatation to valvular function in endurance athletes</article-title>. <source>Br J Sports Med</source> <year>2011</year>; <volume>45</volume>(<issue>3</issue>): <fpage>178</fpage>–<lpage>184</lpage>.</citation></ref>
<ref id="bibr10-1741826711414215"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Basso</surname><given-names>C</given-names></name><name><surname>Ronco</surname><given-names>F</given-names></name><name><surname>Marcus</surname><given-names>F</given-names></name><name><surname>Abudureheman</surname><given-names>A</given-names></name><name><surname>Rizzo</surname><given-names>S</given-names></name><name><surname>Frigo</surname><given-names>A</given-names></name><etal/></person-group>. <source>Eur Heart J</source> <year>2008</year>; <volume>29</volume>: <fpage>2760</fpage>–<lpage>2771</lpage>.</citation></ref>
<ref id="bibr11-1741826711414215"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chimenti</surname><given-names>C</given-names></name><name><surname>Pieroni</surname><given-names>M</given-names></name><name><surname>Maseri</surname><given-names>A</given-names></name><name><surname>Frustaci</surname><given-names>A</given-names></name></person-group>. <article-title>Histologic findings in patients with clinical and instrumental diagnosis of sporadic arrhythmogenic right ventricular dysplasia</article-title>. <source>J Am Coll Cardiol</source> <year>2004</year>; <volume>43</volume>: <fpage>2305</fpage>–<lpage>2313</lpage>.</citation></ref>
<ref id="bibr12-1741826711414215"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Prakken</surname><given-names>NH</given-names></name><name><surname>Velthuis</surname><given-names>BK</given-names></name><name><surname>Teske</surname><given-names>AJ</given-names></name><name><surname>Mosterd</surname><given-names>A</given-names></name><name><surname>Mali</surname><given-names>WP</given-names></name><name><surname>Cramer</surname><given-names>MJ</given-names></name></person-group>. <article-title>Cardiac MRI reference values for athletes and nonathletes corrected for body surface area, training hours/week and sex</article-title>. <source>Eur J Cardiovasc Prev Rehabil</source> <year>2010</year>; <volume>17</volume>: <fpage>198</fpage>–<lpage>203</lpage>.</citation></ref>
<ref id="bibr13-1741826711414215"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Prakken</surname><given-names>NH</given-names></name><name><surname>Cramer</surname><given-names>MJ</given-names></name><name><surname>Teske</surname><given-names>AJ</given-names></name><name><surname>Arend</surname><given-names>M</given-names></name><name><surname>Mali</surname><given-names>WP</given-names></name><name><surname>Velthuis</surname><given-names>BK</given-names></name></person-group>. <article-title>The effect of age in the cardiac MRI evaluation of the athlete's heart</article-title>. <source>Int J Cardiol</source> <year>2011</year>; <volume>149</volume>(<issue>1</issue>): <fpage>68</fpage>–<lpage>73</lpage>.</citation></ref>
<ref id="bibr14-1741826711414215"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mitchell</surname><given-names>JH</given-names></name><name><surname>Haskell</surname><given-names>WL</given-names></name><name><surname>Raven</surname><given-names>PB</given-names></name></person-group>. <article-title>Classification of sports</article-title>. <source>Med Sci Sports Exerc</source> <year>1994</year>; <volume>26</volume>(<issue>Suppl</issue>): <fpage>242</fpage>–<lpage>245</lpage>.</citation></ref>
<ref id="bibr15-1741826711414215"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Prakken</surname><given-names>NH</given-names></name><name><surname>Velthuis</surname><given-names>BK</given-names></name><name><surname>Vonken</surname><given-names>EJ</given-names></name><name><surname>Mali</surname><given-names>WP</given-names></name><name><surname>Cramer</surname><given-names>MJ</given-names></name></person-group>. <article-title>Cardiac MRI: standardized right and left ventricular quantification by briefly coaching inexperienced personnel</article-title>. <source>Open Magn Reson J</source> <year>2008</year>; <volume>1</volume>: <fpage>104</fpage>–<lpage>111</lpage>.</citation></ref>
<ref id="bibr16-1741826711414215"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tandri</surname><given-names>H</given-names></name><name><surname>Macedo</surname><given-names>R</given-names></name><name><surname>Calkins</surname><given-names>H</given-names></name><name><surname>Marcus</surname><given-names>F</given-names></name><name><surname>Cannom</surname><given-names>D</given-names></name><name><surname>Scheinman</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Role of magnetic resonance imaging in arrhythmogenic right ventricular dysplasia: insights from the North American arrhythmogenic right ventricular dysplasia (ARVC/D) study</article-title>. <source>Am Heart J</source> <year>2008</year>; <volume>155</volume>: <fpage>147</fpage>–<lpage>153</lpage>.</citation></ref>
<ref id="bibr17-1741826711414215"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Little</surname><given-names>R</given-names></name></person-group>. <article-title>Regression with missing X's: a review</article-title>. <source>J Am Stat Assoc</source> <year>1992</year>; <volume>87</volume>: <fpage>1227</fpage>–<lpage>1237</lpage>.</citation></ref>
<ref id="bibr18-1741826711414215"><label>18</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Rubin</surname><given-names>D</given-names></name></person-group>. <source>Multiple imputation for nonresponse in surveys</source>. <publisher-loc>Hoboken, New Jersey</publisher-loc>: <publisher-name>John Wiley &amp; Sons</publisher-name>, <year>1987</year>, pp. <fpage>15</fpage>–<lpage>18</lpage>.</citation></ref>
<ref id="bibr19-1741826711414215"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Donders</surname><given-names>AR</given-names></name><name><surname>van der Heijden</surname><given-names>GJ</given-names></name><name><surname>Stijnen</surname><given-names>T</given-names></name><name><surname>Moons</surname><given-names>KG</given-names></name></person-group>. <article-title>Review: a gentle introduction to imputation of missing values</article-title>. <source>J Clin Epidemiol</source> <year>2006</year>; <volume>59</volume>: <fpage>1087</fpage>–<lpage>1091</lpage>.</citation></ref>
<ref id="bibr20-1741826711414215"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Du Bois</surname><given-names>D</given-names></name><name><surname>Du Bois</surname><given-names>EF</given-names></name></person-group>. <article-title>A formula to estimate the approximate surface area if height and weight be known</article-title>. <source><italic>1916. </italic>Nutrition</source> <year>1989</year>; <volume>5</volume>: <fpage>303</fpage>–<lpage>311</lpage>.</citation></ref>
<ref id="bibr21-1741826711414215"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Marcus</surname><given-names>F</given-names></name><name><surname>Basso</surname><given-names>C</given-names></name><name><surname>Gear</surname><given-names>K</given-names></name><name><surname>Sorrell</surname><given-names>VL</given-names></name></person-group>. <article-title>Pitfalls in the diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia</article-title>. <source>Am J Cardiol</source> <year>2010</year>; <volume>105</volume>: <fpage>1036</fpage>–<lpage>1039</lpage>.</citation></ref>
<ref id="bibr22-1741826711414215"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sievers</surname><given-names>B</given-names></name><name><surname>Addo</surname><given-names>M</given-names></name><name><surname>Franken</surname><given-names>U</given-names></name><name><surname>Trappe</surname><given-names>HJ</given-names></name></person-group>. <article-title>Right ventricular wall motion abnormalities found in healthy subjects by cardiovascular magnetic resonance imaging and characterized with a new segmental model</article-title>. <source>J Cardiovasc Magn Reson</source> <year>2004</year>; <volume>6</volume>: <fpage>601</fpage>–<lpage>608</lpage>.</citation></ref>
<ref id="bibr23-1741826711414215"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Whyte</surname><given-names>GP</given-names></name><name><surname>Stephens</surname><given-names>N</given-names></name><name><surname>Senior</surname><given-names>R</given-names></name><name><surname>Peters</surname><given-names>N</given-names></name><name><surname>O'Hanlon</surname><given-names>R</given-names></name><name><surname>Sharma</surname><given-names>S</given-names></name></person-group>. <article-title>Differentiation of RVOT-VT and ARVC in an elite athlete</article-title>. <source>Med Sci Sports Exerc</source> <year>2008</year>; <volume>40</volume>: <fpage>1357</fpage>–<lpage>1361</lpage>.</citation></ref>
<ref id="bibr24-1741826711414215"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bauce</surname><given-names>B</given-names></name><name><surname>Frigo</surname><given-names>G</given-names></name><name><surname>Benini</surname><given-names>G</given-names></name><name><surname>Michieli</surname><given-names>P</given-names></name><name><surname>Basso</surname><given-names>C</given-names></name><name><surname>Folino</surname><given-names>AF</given-names></name><etal/></person-group>. <article-title>Differences and similarities between arrhythmogenic right ventricular cardiomyopathy and athlete's heart adaptations</article-title>. <source>Br J Sports Med</source> <year>2010</year>; <volume>44</volume>: <fpage>148</fpage>–<lpage>154</lpage>.</citation></ref>
<ref id="bibr25-1741826711414215"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Marcus</surname><given-names>FI</given-names></name><name><surname>Zareba</surname><given-names>W</given-names></name><name><surname>Calkins</surname><given-names>H</given-names></name><name><surname>Towbin</surname><given-names>JA</given-names></name><name><surname>Basso</surname><given-names>C</given-names></name><name><surname>Bluemke</surname><given-names>DA</given-names></name><etal/></person-group>. <article-title>Arrhythmogenic right ventricular cardiomyopathy/dysplasia clinical presentation and diagnostic evaluation: results from the North American Multidisciplinary Study</article-title>. <source>Heart Rhythm</source> <year>2009</year>; <volume>6</volume>: <fpage>984</fpage>–<lpage>992</lpage>.</citation></ref>
<ref id="bibr26-1741826711414215"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bluemke</surname><given-names>DA</given-names></name><name><surname>Krupinski</surname><given-names>EA</given-names></name><name><surname>Ovitt</surname><given-names>T</given-names></name><name><surname>Gear</surname><given-names>K</given-names></name><name><surname>Unger</surname><given-names>E</given-names></name><name><surname>Axel</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>MR Imaging of arrhythmogenic right ventricular cardiomyopathy: morphologic findings and interobserver reliability</article-title>. <source>Cardiology</source> <year>2003</year>; <volume>99</volume>: <fpage>153</fpage>–<lpage>162</lpage>.</citation></ref>
<ref id="bibr27-1741826711414215"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tandri</surname><given-names>H</given-names></name><name><surname>Saranathan</surname><given-names>M</given-names></name><name><surname>Rodriguez</surname><given-names>ER</given-names></name><name><surname>Martinez</surname><given-names>C</given-names></name><name><surname>Bomma</surname><given-names>C</given-names></name><name><surname>Nasir</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Noninvasive detection of myocardial fibrosis in arrhythmogenic right ventricular cardiomyopathy using delayed-enhancement magnetic resonance imaging</article-title>. <source>J Am Coll Cardiol</source> <year>2005</year>; <volume>45</volume>: <fpage>98</fpage>–<lpage>103</lpage>.</citation></ref>
<ref id="bibr28-1741826711414215"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bomma</surname><given-names>C</given-names></name><name><surname>Rutberg</surname><given-names>J</given-names></name><name><surname>Tandri</surname><given-names>H</given-names></name><name><surname>Nasir</surname><given-names>K</given-names></name><name><surname>Roguin</surname><given-names>A</given-names></name><name><surname>Tichnell</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Misdiagnosis of arrhythmogenic right ventricular dysplasia/cardiomyopathy</article-title>. <source>J Cardiovasc Electrophysiol</source> <year>2004</year>; <volume>15</volume>: <fpage>300</fpage>–<lpage>306</lpage>.</citation></ref>
<ref id="bibr29-1741826711414215"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sen-Chowdhry</surname><given-names>S</given-names></name><name><surname>Prasad</surname><given-names>SK</given-names></name><name><surname>Syrris</surname><given-names>P</given-names></name><name><surname>Wage</surname><given-names>R</given-names></name><name><surname>Ward</surname><given-names>D</given-names></name><name><surname>Merrifield</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Cardiovascular magnetic resonance in arrhythmogenic right ventricular cardiomyopathy revisited: comparison with task force criteria and genotype</article-title>. <source>J Am Coll Cardiol</source> <year>2006</year>; <volume>48</volume>: <fpage>2132</fpage>–<lpage>2140</lpage>.</citation></ref>
<ref id="bibr30-1741826711414215"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>La Gerche</surname><given-names>A</given-names></name><name><surname>Robberecht</surname><given-names>C</given-names></name><name><surname>Kuiperi</surname><given-names>C</given-names></name><name><surname>Nuyens</surname><given-names>D</given-names></name><name><surname>Willems</surname><given-names>R</given-names></name><name><surname>de Ravel</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Lower than expected desmosomal gene mutation prevalence in endurance athletes with complex ventricular arrhythmias of right ventricular origin</article-title>. <source>Heart</source> <year>2010</year>; <volume>96</volume>: <fpage>1268</fpage>–<lpage>1274</lpage>.</citation></ref>
</ref-list>
</back>
</article>